Zoetis Inc.

NYSE ZTS

Zoetis Inc. Free Cash Flow Yield on January 14, 2025: 3.11%

Zoetis Inc. Free Cash Flow Yield is 3.11% on January 14, 2025, a 69.04% change year over year. Free cash flow yield compares the return from free cash flow to the market cap; higher yield suggests attractive investment.
  • Zoetis Inc. 52-week high Free Cash Flow Yield is 3.15% on December 30, 2024, which is 1.32% above the current Free Cash Flow Yield.
  • Zoetis Inc. 52-week low Free Cash Flow Yield is 1.78% on February 28, 2024, which is -42.90% below the current Free Cash Flow Yield.
  • Zoetis Inc. average Free Cash Flow Yield for the last 52 weeks is 2.44%.
Key data
Date Free Cash Flow Yield Market Value Added (MVA) Price to Book Ratio (P/B) Price to Earnings Ratio (P/E)
Market news
Loading...
NYSE: ZTS

Zoetis Inc.

CEO Ms. Kristin C. Peck
IPO Date Feb. 1, 2013
Location United States
Headquarters 10 Sylvan Way
Employees 14,100
Sector Health Care
Industries
Description

Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. The company also offers vaccines, which are biological preparations to prevent diseases of the respiratory, gastrointestinal, and reproductive tracts or induce a specific immune response; anti-infectives that prevent, kill, or slow the growth of bacteria, fungi, or protozoa; and parasiticides that prevent or eliminate external and internal parasites, which include fleas, ticks, and worms. It also provides other pharmaceutical products that comprise pain and sedation, antiemetic, reproductive, and oncology products; dermatology products for itch associated with allergic conditions and atopic dermatitis; and medicated feed additives, which offer medicines to livestock. In addition, the company provides portable blood and urine analysis testing, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, including nutritionals and agribusiness services, as well as products and services in areas, such as biodevices, genetics tests, and precision animal health. It markets its products to veterinarians, livestock producers, and retail outlets, as well as third-party veterinary distributors through its sales representatives, and technical and veterinary operations specialists. The company was founded in 1952 and is headquartered in Parsippany, New Jersey.

Similar companies

ITCI

Intra-Cellular Therapies, Inc.

USD 126.89

-0.24%

ALVO

Alvotech

USD 13.31

0.68%

NBIX

Neurocrine Biosciences, Inc.

USD 139.51

-2.46%

EBS

Emergent BioSolutions Inc.

USD 9.36

-0.53%

VTRS

Viatris Inc.

USD 11.72

-0.68%

ELAN

Elanco Animal Health Incorporated

USD 11.70

0.00%

AMPH

Amphastar Pharmaceuticals, Inc.

USD 38.48

1.48%

StockViz Staff

January 15, 2025

Any question? Send us an email